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A b s t r a c t
Epigenetic alterations have been implicated in cancer development. DNA methylation modulates gene expression, 
which is catalyzed by DNA methyltransferases (DNMTs). The objective of our study was to evaluate expression 
of DNMTs in medulloblastoma and analyze its correlation with clinical features. Nuclear expression of DNMT1, 
DNMT3A and DNMT3B was analyzed in human primary medulloblastoma of 44 patients using immunohistochem-
istry. Correlation of expression of DNMT levels with classical histological subtypes, novel molecular subgroups and 
survival of patients was analyzed. Elevated expression of DNMT1, DNMT3A and DNMT3B was observed in 63.64%, 
68.18% and 72.73% of all cases, respectively. None of them showed a correlation with classical histology or survival. 
Concerning molecular subtypes, significantly higher expression of DNMT1 was observed in the SHH group compared 
to non-SHH samples (p = 0.02), but without significant difference in DNMT3A or DNMT3B levels between any sub-
types. In conclusion, DNMT1, DNMT3A and DNMT3B are highly expressed in human medulloblastoma samples, sug-
gesting that promoter hypermethylation may play a role in medulloblastoma development. Demethylation of tumor 
suppressor gene promoters may be considered as a possible future target in therapy of medulloblastoma.
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Introduction
Medulloblastoma (MB) is the most frequent 
malignant brain tumor in childhood, with various 
histological appearances. There are non-overlapping 
histological (classic, desmoplastic, extensive nodular, 
large cell/anaplastic) and molecular classifications 
(SHH, WNT, Group 3 and 4) for medulloblastoma 
[3,6,11,23,25,27,34]. Despite multimodal therapies, 
the 70-75% long-term survival rate has not been 
exceeded yet in high-risk patients [13,29,34]. A more 
precise classification of patients would help to devel-
op a  more effective treatment strategy and reduce 
side effects [3,11,23].
There is emerging evidence that epigenetic chang-
es contribute to carcinogenesis. The most important 
mechanisms of epigenetic alteration are DNA meth-
ylation, histone modification and microRNA regula-
tion. DNA methyltransferases (DNMTs) are enzymes 
transferring methyl groups to cytosine in CpG dinu-
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cleotides, resulting in gene silencing. The DNMT 
family has three active members: DNMT1, DNMT3A 
and DNMT3B. DNMT3A and DNMT3B are regarded 
as de novo methyltransferases, whilst DNMT1 reacts 
on hemimethylated DNA, copying the methylation 
pattern during replication. Generally, tumor cells are 
characterized by global hypomethylation and hyper-
methylation of certain gene promoters. Therefore, 
repetitive elements are hypomethylated and spe-
cific tumor suppressor genes are repressed due to 
hypermethylation. These may contribute to chromo-
somal instability and abnormal gene silencing that 
could promote tumor-initializing steps [2,9,14,28,38]. 
Promoter hypermethylation of tumor suppressor 
genes and DNA repair genes has been observed in 
a wide variety of tumors, such as colorectal, breast 
cancer, glioma and medulloblastoma [19,22,36]. 
Overexpression of DNMTs was detected at the mRNA 
or protein level. Increased DNMT1 expression was 
described in gastric cancers, along with DNMT3A in 
breast and pancreatic cancer, or along with DNMT3B 
in glioma [8,16,30,38,39]. Although there is emerging 
evidence that epigenetic events play a  remarkable 
role in the development of adult cancers, our knowl-
edge about their role in pediatric brain tumors is still 
very limited.
DNA methylation studies in medulloblastoma 
have focused on the role of tumor suppressor genes 
in the development of brain tumors, and shed light 
on contradictory results in the majority of genes, 
except for RASSF1A [37]. Recent studies indicate that 
the DNA methylation profile can be used for MB sub-
grouping and disease risk assessment [18,35].
The aims of our study are to characterize the 
expression of DNMTs in human medulloblastoma 
samples and their potential prognostic role in surviv-
al of patients. Possible correlations of DNMT proteins 
and clinicopathological features are also analyzed.
Material and methods
Medulloblastoma tissue samples
Formalin-fixed, paraffin-embedded MB tumor 
samples were collected from the National Insti-
tute of Neurosciences (Budapest, Hungary) and 
1st Institute of Pathology and Experimental Cancer 
Research, Semmelweis University (Budapest, Hun-
gary). Forty-four primary medulloblastoma samples 
removed surgically between 2004 and 2010 and 
related clinical data of patients derived from the 
Hungarian Pediatric Cancer Registry were used. 
The study was approved by the Ethics Committee 
of the Institutional Ethical Review Board of Sem-
melweis University (TUKEB No. 30/2015).
Tissue microarray (TMA) construction 
and immunohistochemistry
Hematoxylin and eosin (HE) stained sections 
were reviewed by a neuropathologist to select rep-
resentative areas for producing TMA. TMA blocks 
were created by a  computer-controlled TMA Mas-
ter (3DHISTECH, Budapest, Hungary) instrument. 
Depending on sample quality one or two cores of 
representative areas with a diameter of 2 mm were 
taken from each tumor sample. From the TMA blocks 
4 μm sections were created. Sections were depar-
affinized, rehydrated, and endogenous peroxidase 
activity was blocked. Heat-induced antigen retriev-
al was performed with Tris-EDTA buffer (pH = 9.0) 
for 45 min in a  microwave oven. Sections were 
incubated overnight using anti-DNMT1 antibody 
(dilution 1 : 200; Ab19905, Abcam, Cambridge, UK), 
anti-DNMT3A antibody (dilution 1 : 600; Ab13888, 
Abcam, Cambridge, UK) and anti-DNMT3B antibody 
(dilution 1 : 200; Ab13604, Abcam, Cambridge, UK) 
diluted in 5% BSA containing Tris-buffered saline 
(TBS; pH = 7.4). Antigen development was per-
formed by Novolink Polymer Detection System 
(Novocastra, Wetzlar, Germany) following the man-
ufacturer’s instructions. Reactions were visualized 
by 3,3’-diaminobenzidine (DAB) (DAKO, Denmark) 
as a substrate, and then slides were counterstained 
by hematoxylin. Tonsil for DNMT1, and kidney for 
DNMT3A and DNMT3B were used as positive tissue 
controls.
For determination of the WNT subgroup 
anti-β-catenin antibody (dilution 1 : 150; M-3539, 
DAKO, Denmark) and of the SHH subgroup anti- 
secreted frizzled-related protein 1 (SFRP1) antibody 
(dilution 1 : 1500; ab-4193, Abcam, Cambridge, UK), 
characteristic proteins of these pathways, were 
applied. Immunohistochemical reactions were exe-
cuted as described above, but antigen retrieval was 
performed in TE buffer boiled in a pressure cooker 
for 20 minutes.
Evaluation of immunostaining
Slides were digitalized by a  Pannoramic Scan 
instrument and examined by Pannoramic Viewer 
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software (3DHISTECH, Budapest, Hungary). To eval-
uate DNMT expression only nuclear staining was 
considered. Intensity of staining and rate of positive 
cells were calculated from 1,000 cells in a represen-
tative area of each sample. According to the intensi-
ty of staining, four values were created: 0 (negative), 
1 (weak), 2 (moderate) and 3 (strong). The proportion 
of positive cells was ranked in five groups: 0 (neg-
ative), 1 (1-25%), 2 (26-50%), 3 (51-75%) and 4 (76-
100%). The products of the two values (0-12) were 
divided into two groups: 0-3 regarded as no/weak 
expression and 4-12 regarded as moderate/strong 
expression. Samples were classified into WNT or 
SHH subgroups when the proportion of positive cells 
with nuclear β-catenin or negative nuclear β-catenin 
and positive SFRP1 staining was above 10% [7,27].
Statistical analysis
All statistical analysis was performed using Sta-
tistica software (StatSoft Inc., Tulsa, OK, USA). Sur-
vival of patients was calculated by the Kaplan-Meier 
method. Correlation of expression of DNMTs and 
survival was examined by the log-rank test. Correla-
tion of expression of each DNMT was analyzed by 
the Spearman rank order test. Correlation of expres-
sion of DNMTs and age, gender, histological sub-
type or molecular subgroups was examined by the 
Mann-Whitney U-test and Fisher’s exact test, when 
appropriate. Results were considered statistically 
significant when the p value was less than 0.05.
Results
Patients’ data
Demographic characteristics of the studied 
cohort are summarized in Table I. Median age of 
44 patients was 8.5 years (range 1.1-28.7 years). 
The proportion of male patients was 55%. Histologi-
cally, 84.1%, 11.4% and 4.5% of patients showed clas-
sic, desmoplastic and large cell/anaplastic (L/A) type 
of medulloblastoma, respectively. Survival data were 
available in 40 patients (90.9%). Median follow-up 
time was 5.6 years (range 0-9.7 years). Patients were 
treated according to the Hungarian MBL2004/2008 
schedules [15]. There is no standard treatment for 
adults with medulloblastoma in Hungary. Patients 
are treated according to the individual decision of 
each treating physician, and these treatment details 
are poorly accessible in Hungary. Therefore, adult 
patients were omitted from the survival analysis.
Expression of DNMTs in human 
medulloblastoma
Elevated (moderate/strong) expression of DNMT1, 
DNMT3A and DNMT3B was observed in 63.64%, 
68.18% and 72.73% of patients, respectively (Table I). 
Representative stains are shown in Figure 1. The re- 
lationship of histology and DNMT expression was 
evaluated only in the classic and desmoplastic type. 
Moderate/strong expression of DNMT1 was detect-
ed in 62.2% of classic and 60.0% of desmoplastic, of 
DNMT3A in 70.3% of classic and 60.0% of desmo-
plastic, and of DNMT3B in 70.3% of classic and 80.0% 
of desmoplastic samples. We could analyze only two 
samples of L/A subtype. Both of them showed mod-
erate/strong expression for DNMT1 and DNMT3B, 
but only one for DNMT3A.
Correlation between DNMT expression 
and patients’ data
There was no correlation between the expression 
of DNMT1, DNMT3A and DNMT3B and age at disease 
onset or gender or histological subtype (Table II). 
Kaplan-Meier curves, based on different expres-
sion of DNMTs, did not show a  significant differ-
ence in overall survival (Fig. 2). None of the DNMTs 
could be used as a  prognostic marker for medul-
loblastoma in our cohort. DNMT1 and DNMT3A 
(p = 0.08), or DNMT1 and DNMT3B (p = 0.17) or 
DNMT3A and DNMT3B (p = 0.69) did not show 
a co-expression pattern. Expression of nuclear β-cat-
enin was shown only in one patient (2.3%) with weak 
staining. There were 12 (27.3%) patients belonging to 
SHH subgroup according to their cytoplasmic, mem-
branous or secreted SFRP1 expression and lack of 
nuclear β-catenin (Table I). Expression of DNMT1 in 
the SHH subgroup compared to the non-WNT/non-
SHH subgroup of patients was significantly higher 
(p = 0.02), whereas expression of DNMT3A and 
DNMT3B did not differ significantly between different 
groups (p = 0.78 and p = 0.17, respectively, Table II).
Discussion
In recent years a new prognostic classification of 
medulloblastoma was introduced by molecular find-
ings, whilst there are still several twists in this clas-
sification system. It is still motivating to find further 
prognostic markers [3,6,11,23,25,27,34]. Nowadays, 
an exact diagnosis of pediatric brain tumors can be 
established based on the methylation profile of dif-
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Table I. Characteristics of patients and results of immunohistochemical staining of DNMTs, β-catenin, and SFRP1
Gender Histology Age at disease 
onset (years)
State Survival 
(years)
DNMT1* DNMT3A* DNMT3B* β-catenin SFRP1
1 F Classic 1.18 Dead 0.18 0 0 0 Negative Negative 
2 M L/A 7.84 Dead 1.47 9 4 6 Negative Positive 
3 F Classic 5.99 Dead 4.56 4 9 3 Negative Negative 
4 F Classic 14.04 Dead 0.00 4 6 8 Negative Negative 
5 M Classic 10.81 Dead 7.98 4 8 8 Negative Positive 
6 F Classic 3.31 Alive 9.38 6 8 12 Negative Negative 
7 M Classic 13.54 Alive 9.74 8 12 12 Negative Negative 
8 M Classic 17.09 Alive 8.99 2 0 8 Negative Positive 
9 F Classic 10.09 Dead 3.07 2 8 8 Negative Negative 
10 M Desmoplastic 14.54 Alive 9.08 1 2 3 Negative Negative 
11 M Desmoplastic 5.14 Dead 0.59 4 4 6 Negative Negative 
12 F Classic 17.90 Dead 5.02 4 2 8 Negative Negative 
13 M Classic 3.11 Dead 0.92 2 1 4 Negative Negative 
14 F Classic 4.71 Alive 8.54 4 6 12 Negative Negative 
15 M Classic 15.30 Alive 7.80 2 4 2 Positive Negative 
16 F Classic 8.48 Alive 7.24 12 2 2 Negative Negative 
17 F Classic 14.28 Alive 8.09 4 8 8 Negative Negative 
18 M Desmoplastic 6.63 Alive 7.90 3 12 8 Negative Positive 
19 M L/A 13.84 Dead 1.94 4 3 12 Negative Positive 
20 M Desmoplastic 4.34 Dead 0.09 9 12 4 Negative Negative 
21 M Classic 8.56 Alive 7.00 2 4 12 Negative Negative 
22 M Classic 15.46 Alive 6.52 2 8 12 Negative Negative 
23 M Desmoplastic 2.59 Alive 6.52 4 2 4 Negative Positive 
24 M Classic 4.50 Dead 1.92 4 12 3 Negative Negative 
25 F Classic 9.30 Dead 5.54 8 12 12 Negative Negative 
26 M Classic 6.81 Alive 6.63 4 2 3 Negative Negative 
27 F Classic 8.50 Alive 6.07 8 0 12 Negative Negative 
28 M Classic 7.70 Alive 6.02 2 8 8 Negative Negative 
29 F Classic 1.77 Alive 6.76 9 8 8 Negative Positive 
30 F Classic 4.92 Alive 6.56 6 8 6 Negative Negative 
31 M Classic 22.90 NA NA 6 4 8 Negative Positive 
32 M Classic 10.76 Dead 5.22 2 2 4 Negative Negative 
33 F Classic 21.43 NA NA 6 0 12 Negative Positive 
34 F Classic 16.71 Alive 5.67 2 12 1 Negative Negative 
35 M Classic 7.92 Alive 5.48 1 1 4 Negative Negative 
36 F Classic 10.75 Alive 5.65 4 4 3 Negative Negative 
37 F Classic 1.78 Dead 0.48 2 8 6 Negative Negative 
38 M Classic 4.63 Alive 4.99 4 3 4 Negative Negative 
39 M Classic 28.25 NA NA 9 4 6 Negative Positive 
40 F Classic 1.07 Alive 3.23 6 12 3 Negative Negative 
41 F Classic 2.84 Alive 3.12 2 8 2 Negative Negative 
42 M Classic 13.18 Alive 2.80 2 8 8 Negative Negative 
43 F Classic 28.69 NA NA 9 12 2 Negative Positive 
44 M Classic 9.68 Alive 2.12 9 12 12 Negative Positive 
*Product of intensity (0-3) and rate of positive cells (0-4), maximal value: 12 SFRP1 – secreted frizzled-related protein 1, DNMT – DNA methyltransferase,  
M – male, F – female, L/A – large cell/anaplastic, NA – not available
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A B
Fig. 1. Representative immunohistochemical staining of DNMTs in medulloblastoma. A) Negative staining 
of DNMT3A. B, C, D) Moderate/strong immunopositivity of DNMT1, DNMT3A and DNMT3B, respectively.
C D
Table II. Evaluation of patients’ characteristics and expression of different DNMTs. Correlation of DNMTs 
and clinical features are shown by probability value (p)
All DNMT1 p DNMT3A p DNMT3B p
No/
Weak
Moderate/
Strong
No/
Weak
Moderate/
Strong
No/
Weak
Moderate/
Strong
Number of patients 44 16
(36.36%)
28 
(63.64%)
0.91a
14 
(31.82%)
30 
(68.18%)
0.91a
12 
(27.27%)
32 
(72.73%)
0.65a
Median age 
of patients (years)
8.53 9.33 8.49 8.49 8.93 7.65 8.93
Gender
Male 24 11 13
0.21b
9 15
0.52b
4 20
0.10b
Female 20 5 15 5 15 8 12
Histological subtype
Classic 37 14 23
1.00b
11 26
0.64b
11 26
1.00b
Desmoplastic 5 2 3 2 3 1 4
Large cell/anaplastic 2 0 2 # 1 1 # 0 2 #
Molecular subtype
Wnt 1 1 0 # 0 1 # 1 0 #
Shh 12 2 10
0.02a *
4 8
0.78a
1 11
0.17a
Non-Wnt/non-Shh 21 13 18 10 21 10 21
aMann-Whitney U-test, bFisher’s exact test, two-tailed, # – not applicable, * – statistically significant
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Fig. 2. Kaplan-Meier survival curves for DNMT1 
(A), DNMT3A (B) and DNMT3B (C) expression. 
Presence of DNMTs did not influence survival in 
our patient cohort (without adult patients). 
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ferent tumor types [18,21,35]. DNMTs are respon-
sible for DNA methylation, an important epigenetic 
regulation process, which contributes to develop-
ment of cancer. DNMT1 is responsible for mainte-
nance of methylation patterns during DNA repli-
cation. DNMT3A and DNMT3B are regarded as de 
novo methyl-transferases and abundantly expressed 
during embryonic development [2,9,14,19,22,28,38].
In our study, expression of three members of 
the DNMT family (DNMT1, DNMT3A, DNMT3B) in me-
dulloblastoma samples and their possible effect on 
disease outcome were examined. During the devel-
opment and progression of MB, the biological role 
of DNMTs, crucial regulators of the methylation pat-
tern, is not completely understood yet. In our study, 
the correlation of expression of these enzymes at 
the protein level and clinical data of MB patients 
were investigated.
In our experiments elevated expression of all 
DNMTs was observed in most of the MB samples. 
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Correlation of expression of DNMTs and histologi-
cal subtype of MB, age at disease onset or gender 
was not proven in our experience. Increased DNMT1 
expression indicates worse outcomes in several 
types of cancers, such as gastric cancer, hepatocel-
lular carcinomas and pancreatic ductal adenocarci-
noma [10,26,33]. In contrast, our analysis showed 
no difference in disease outcome when comparing 
patients with no/weak and moderate/strong expres-
sion of three DNMTs, so DNMTs are not predictive 
markers for medulloblastoma survival. The different 
result may be due to the different biological nature 
of medulloblastoma and above-mentioned tumor 
types. While there are some common dysregulated 
signaling pathways (WNT, SHH, Notch) in medullo-
blastoma and in these other cancer types, differenc-
es could also be observed in regulation of the follow-
ing pathways: in gastric cancer altered EGFR, ErbB, 
mTOR, VEGF, HGF/MET pathways, etc.; in hepatocel-
lular carcinoma altered Ras/Raf/MAPK, mTOR, etc.; 
and in pancreatic ductal adenocarcinoma FGF, Notch, 
TGF-β, EGF and retinoid signaling [1,31,32].
The SHH subgroup of MB is characterized by the 
expression of SFRP1 and lack of nuclear β-catenin 
[17,27]. Our results indicate that SHH pathway acti-
vation is associated with elevated DNMT1 expres-
sion, which could be a consequence of upregulation 
of DNMT1 by SHH in SHH-associated medulloblas-
tomas. Similar observations were made in pancre-
atic cancer and in myelodysplastic syndrome (MDS) 
[16,40]. DNMT1 and DNMT3A could be regulated 
by Gli1, an effector of the SHH signaling pathway. 
The SHH pathway was inhibited in pancreatic 
cancer and MDS cell lines, resulting in decreased 
DNMT1 expression, whereas induction of the SHH 
pathway resulted in higher DNMT1 expression 
[16,40]. In contrast, DNMT1 inhibition resulted in 
increased expression of SFRP1 in MB cell lines [20]. 
One explanation could be that investigated MB cell 
lines do not belong to the SHH subgroup, since 
they showed lower levels of SFRP1 compared to the 
SHH subgroup. Among non-WNT/non-SHH patients, 
other mechanisms could result in DNMT1 activa-
tion. Further studies are needed to clarify the rela-
tionship between regulation of DNA methylation 
and SHH signaling pathway.
Theoretically, inhibition of DNA methylation is 
a therapeutic opportunity by reversing gene silenc-
ing [9,12,14,38]. An in vitro experiment showed that 
the DNMT inhibitor 5-aza-2’-deoxycytidine (decit-
abine) reactivates the tumor suppressor PTCH1 gene 
in the MB cell line [4]. A combination of DNMT and 
histone deacetylase (HDAC) inhibitors was effective 
to prevent MB development in Ptch knockout mice, 
while in advanced stage tumors this therapy was 
less efficient [5]. Epigenetic modulators combined 
with multi-kinase inhibitor could enhance apoptosis 
in vitro in medulloblastoma cells [24].
In conclusion, this is the first study to analyze 
DNMT expression in medulloblastoma in terms of 
expression level and correlation with clinical data. 
Elevated expression of DNMTs in human medullo-
blastoma, and association of DNMT1 and SHH sub-
groups were observed, without an effect on survival. 
Based on increased expression of DNMTs in me dul-
loblastoma, their inhibition has potential for further 
investigation to optimize therapy of medullobla-
stoma.
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